Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 13 July 2023

 
 
 
   

News

 
Thumbnail

Access to oncology combination therapies in Europe: Today's challenges and solutions
13 July 2023

Despite the significant value combination therapies bring to cancer care, there are several challenges to their access... Read more

Thumbnail

Joint Position Paper on the Hospital Exemption Scheme for ATMPs
13 July 2023

Our organisations are committed to engage with policymakers and interested stakeholders for an inclusive and solutions-driven... Read more

Thumbnail

EFPIA response to European Parliament position on EMA Fees Regulation
12 July 2023

EFPIA welcomes the adoption of the EMA Fees regulation report by the European Parliament at the July Plenary session... Read more

Thumbnail

EFPIA statement on the EU-New Zealand FTA
11 July 2023

We remain hopeful that the two sides will establish alternative platforms and dialogues where further discussions can... Read more

Thumbnail

Biopharma SMEs need clear incentives and stable legislation for Europe to remain competitive...
07 July 2023

A new survey published today by EFPIA details the financial environment that SMEs need to thrive in Europe and compete... Read more

 
 
 
   

Blogs

 

Unlocking the potential of precision oncology (Guest Blog)
12 July 2023 - Ivana Cattaneo

The potential of precision oncology is there. To unleash it, we need to move forward together, working on ways to advance... Read more

Implementing cancer screening across the EU (Guest Blog)
12 July 2023 - Eduardo Pisani

The implementation of cancer screening programmes represents one of the policies that can make a meaningful improvement... Read more

 
 
 
   

Events

 

Rethinking Alzheimer’s disease: Moving towards a new Alzheimer’s disease detection and diagnosis...
26 September 2023 (Online)

Moving towards a new Alzheimer’s disease detection and diagnosis pathway Read more

DIA Medical Information and Communications Conference
27 September 2023 (Brussels)

Engage and exchange with the biggest medical information community in Europe Read more

 
 
 
   

Rare Diseases Moonshot: Clinical trials research needs recommendations

The drug development process for rare diseases is known to present both opportunities and challenges. Because of the small patient pool available in these indications, there are challenges in designing and conducting clinical trials to generate the appropriate evidence, analyse and interpret the data, and ultimately meet the regulators’ expectations. The Clinical Trials Research Needs Recommendations, put together by the the Rare Disease Moonshot partners, aim to inform funders, researchers, patients, industry and other stakeholders on where public-private partnerships (PPPs) would bring most value in optimising clinical trials in small and very small populations and points to consider when setting up such collaborations.

 

 
 
 
 
   

What we are reading

 
If the Commission goes ahead with its plans, we run the risk that every European will have...
On 06 July 2023 (Les Echos)

EFPIA President Lars Fruergaard Jørgensen says the European Commission's proposals risk making innovation simply... Read more